Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 2
2017 1
2019 2
2020 1
2021 3
2022 5
2023 6
2024 5
2025 7
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Path-IO
Page 1
AI-enabled virtual spatial proteomics from histopathology for interpretable biomarker discovery in lung cancer.
Li Z, Li Y, Xiang J, Wang X, Yang S, Zhang X, Eweje F, Chen Y, Luo X, Li Y, Mulholland J, Bergstrom C, Kim T, Olguin FM, Willens S, Nirschl JJ, West R, Neal J, Diehn M, Li R. Li Z, et al. Nat Med. 2026 Jan;32(1):231-244. doi: 10.1038/s41591-025-04060-4. Epub 2026 Jan 5. Nat Med. 2026. PMID: 41491099 Free PMC article.
HEX demonstrates substantial performance gains over alternative methods for protein expression prediction from H&E images. We develop a multimodal data integration approach that combines the original H&E image and AI-derived virtual spatial pro …
HEX demonstrates substantial performance gains over alternative methods for protein expression prediction from H&E images. …
Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response.
Chen Z, Wang X, Jin Z, Li B, Jiang D, Wang Y, Jiang M, Zhang D, Yuan P, Zhao Y, Feng F, Lin Y, Jiang L, Wang C, Meng W, Ye W, Wang J, Qiu W, Liu H, Huang D, Hou Y, Wang X, Jiao Y, Ying J, Liu Z, Liu Y. Chen Z, et al. NPJ Precis Oncol. 2024 Mar 22;8(1):73. doi: 10.1038/s41698-024-00579-w. NPJ Precis Oncol. 2024. PMID: 38519580 Free PMC article.
To address this challenge, we curated a dataset from matched mIHC and H&E whole-slide images (WSIs) and developed a deep learning model for automated segmentation of TLSs. ...Furthermore, when applied to biopsied treatment-naive tumor samples, higher TLS ratios …
To address this challenge, we curated a dataset from matched mIHC and H&E whole-slide images (WSIs) and developed a deep l …
Computationally integrating radiology and pathology image features for predicting treatment benefit and outcome in lung cancer.
Vaidya P, Khorrami M, Bera K, Fu P, Delasos L, Gupta A, Barrera C, Pennell NA, Velcheti V, Madabhushi A. Vaidya P, et al. NPJ Precis Oncol. 2025 Jun 4;9(1):161. doi: 10.1038/s41698-025-00939-0. NPJ Precis Oncol. 2025. PMID: 40467921 Free PMC article.
Lung cancer, the leading cause of cancer-related deaths globally, includes non-small cell lung cancer (NSCLC) (85% of cases) and small cell lung cancer (SCLC) (13-15%). ...This study explored the combined use of radiomics from CT scans an …
Lung cancer, the leading cause of cancer-related deaths globally, includes non-small cell lung cancer ( …
Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy.
Shi Y, Shin DS. Shi Y, et al. Biomolecules. 2023 Jun 13;13(6):984. doi: 10.3390/biom13060984. Biomolecules. 2023. PMID: 37371564 Free PMC article. Review.
Molecularly targeted therapeutics and immunotherapy revolutionized the clinical care of NSCLC patients. However, not all NSCLC patients harbor molecular targets (e.g., mutated EGFR), and only a subset benefits from immunotherapy. Moreover, we are lacking reli …
Molecularly targeted therapeutics and immunotherapy revolutionized the clinical care of NSCLC patients. However, not all NSCLC …
A new AI-assisted scoring system for PD-L1 expression in NSCLC.
Huang Z, Chen L, Lv L, Fu CC, Jin Y, Zheng Q, Wang B, Ye Q, Fang Q, Li Y. Huang Z, et al. Comput Methods Programs Biomed. 2022 Jun;221:106829. doi: 10.1016/j.cmpb.2022.106829. Epub 2022 Apr 23. Comput Methods Programs Biomed. 2022. PMID: 35660765
BACKGROUND: Artificial intelligence (AI) analysis may serve as a scoring tool for programmed cell death ligand-1 (PD-L1) expression. In this study, a new AI-assisted scoring system for pathologists was tested for PD-L1 expression assessment in non …
BACKGROUND: Artificial intelligence (AI) analysis may serve as a scoring tool for programmed cell death ligand-1 (PD-L1) expre …
Assessment of PD-L1 expression and tumour infiltrating lymphocytes in early-stage non-small cell lung carcinoma with artificial intelligence algorithms.
Molero A, Hernandez S, Alonso M, Peressini M, Curto D, Lopez-Rios F, Conde E. Molero A, et al. J Clin Pathol. 2025 Jun 19;78(7):456-464. doi: 10.1136/jcp-2024-209766. J Clin Pathol. 2025. PMID: 39419594 Free PMC article.
AIMS: To study programmed death ligand 1 (PD-L1) expression and tumour infiltrating lymphocytes (TILs) in patients with early-stage non-small cell lung carcinoma (NSCLC) with artificial intelligence (AI) algorithms. ...CONCLUSIONS: This preliminary study supp …
AIMS: To study programmed death ligand 1 (PD-L1) expression and tumour infiltrating lymphocytes (TILs) in patients with early- …
Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.
Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, Dries R, Almonte C, Herter-Sprie GS, Santos A, Feeney NB, Paweletz CP, Kulkarni MM, Bass AJ, Rustgi AK, Yuan GC, Kufe DW, Jänne PA, Hammerman PS, Sholl LM, Hodi FS, Richards WG, Bueno R, English JM, Bittinger MA, Wong KK. Lizotte PH, et al. JCI Insight. 2016 Sep 8;1(14):e89014. doi: 10.1172/jci.insight.89014. JCI Insight. 2016. PMID: 27699239 Free PMC article.
Immune checkpoint blockade improves survival in a subset of patients with non-small-cell lung cancer (NSCLC), but robust biomarkers that predict response to PD-1 pathway inhibitors are lacking. Furthermore, our understanding of the divers …
Immune checkpoint blockade improves survival in a subset of patients with non-small-cell lung cancer ( …
Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
Stein MK, Oluoha O, Patel K, VanderWalde A. Stein MK, et al. J Pers Med. 2021 Jun 5;11(6):518. doi: 10.3390/jpm11060518. J Pers Med. 2021. PMID: 34198738 Free PMC article. Review.
While focusing on alterations leading to approvals in a tumor-agnostic fashion (MSI-h, TMB-h, NTRK) and on those alterations with approvals in multiple malignancies (BRAF, ERBB2, RET, BRCA, PD-L1), we also describe several biomarkers or indications tha …
While focusing on alterations leading to approvals in a tumor-agnostic fashion (MSI-h, TMB-h, NTRK) and on those alterations w …
A tissue and cell-level annotated H&E and PD-L1 histopathology image dataset in non-small cell lung cancer.
Spronck J, van Eekelen L, van Midden D, Bogaerts J, Tessier L, Dechering V, Demirel-Andishmand M, de Souza GS, Nemeth R, Munari E, Bogina G, Girolami I, Eccher A, Acs B, Boyaci C, Klubickova N, Looijen-Salamon M, Vos S, Ciompi F. Spronck J, et al. IEEE J Biomed Health Inform. 2026 Apr 20;PP. doi: 10.1109/JBHI.2026.3685529. Online ahead of print. IEEE J Biomed Health Inform. 2026. PMID: 42009323
The tumor immune microenvironment (TIME) in non-small cell lung cancer (NSCLC) histopathology contains morphological and molecular characteristics predictive of immunotherapy response. ...To the best of our knowledge, this i …
The tumor immune microenvironment (TIME) in non-small cell lung cancer (NSCLC) histopathology cont …
What practicing pathologists and oncologists should know about the new computational pathology-based companion diagnostic tools.
Montezuma D, Oliveira SP, Zlobec I, Khalili N, Temprana-Salvador J, Leh S, Ameisen D, Șerbănescu MS, Prelaj A, Kather JN, Zerbe N, L'Imperio V. Montezuma D, et al. J Pathol. 2026 Jun;269(2):143-148. doi: 10.1002/path.70045. Epub 2026 Feb 25. J Pathol. 2026. PMID: 41736658 Free PMC article. Review.
More recent applications have moved beyond mimicry, aiming to predict established biomarkers, such as microsatellite instability or IHC-based markers, and to tackle even more ambitious tasks, such as directly predicting patient prognosis from H&E whole slide ima …
More recent applications have moved beyond mimicry, aiming to predict established biomarkers, such as microsatellite instability or IHC-base …
37 results